Cargando…
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
The treatment of metastatic renal cell carcinoma (RCC) and urothelial carcinoma (UC) remains a major challenge. Past research has implicated the immune system in tumor surveillance of both malignancies, leading to the application of immunotherapy agents for both cancers. Among them, the most promisi...
Autores principales: | Shao, Zhiying, Wang, Andrew Z., George, Daniel J., Zhang, Tian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730869/ https://www.ncbi.nlm.nih.gov/pubmed/29264195 http://dx.doi.org/10.1016/j.ajur.2016.08.013 |
Ejemplares similares
-
Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017) -
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017) -
The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019) -
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
por: Zhu, Jason, et al.
Publicado: (2018) -
Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
por: Anraku, Tsutomu, et al.
Publicado: (2023)